AI-Powered Heart Failure Diagnosis Company Ultromics Secures $55M Series C to Scale its Platform

Ultromics, a heart failure detection company born at the University of Oxford, led by Dr. Ross Upton(Founder and Chief Executive Officer), Prof. Paul Leeson(Founder and Chief Medical Officer), John Russell(Chairman), Dr. Helen Routh(Non-Executive Director), Amir Hasan(Chief Operating Officer), Dr. Gary Woodward(Chief Product Officer), Roger Owens(Chief Commercial Officer), Dr. Nancy Spagou(Chief Experience Officer), and Dr. Jaco Jacobs(Chief Regulatory and Compliance Officer), has secured $55 million in Series C financing co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine’s venture investment vehicle (UCM Ventures) and UPMC Enterprises, also participated in the round. 

Ultromics offers the first FDA-cleared, Medicare-reimbursed AI for detecting HFpEF and cardiac amyloidosis—two hard-to-diagnose heart conditions—built on years of clinical research and extensive echo data. Now expanding across U.S. hospitals and echo labs, the company is also growing its pipeline to cover more cardiac conditions, new distribution channels, and deeper health system partnerships.

Heart failure is on the rise, with costs projected to exceed $70B by 2030 and millions going undiagnosed—especially in elusive forms like HFpEF and cardiac amyloidosis. Up to 64% of HFpEF cases are missed, and amyloidosis is often misdiagnosed, delaying treatment. Reliance on subjective echo interpretation contributes to these gaps, even when patients are actively seeking care.

Ultromics has analyzed over 430,000 echocardiograms and shown significant clinical impact—improving HFpEF detection by 73.6% and outperforming standard risk scores for cardiac amyloidosis in a global study published in the European Heart Journal.

Ultromics is gaining momentum with leading institutions like UChicago Medicine, Northwestern, and Mayo Clinic, forming regional hubs of adoption in high-prevalence areas. Its platform helps hospitals cut unnecessary testing, streamline workflows, and start treatment earlier for better, more cost-effective care.

Ultromics has expanded rapidly, gaining FDA Breakthrough Device clearance for EchoGo® Amyloidosis and launching EchoGo® Score to enhance HFpEF detection. With Medicare reimbursement now covering both outpatient and inpatient use, the company is well-positioned for scaled adoption across U.S. hospitals.